Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.
Cardiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
J Invasive Cardiol. 2024 Jun;36(6). doi: 10.25270/jic/24.00011.
Valve oversizing has been associated with reduced paravalvular leaks (PVL) and valve migration risk. However, no optimal cut-off oversizing value has been defined for the Evolut system (Medtronic). The aim of this study was to assess the relationship between the degree of oversizing and moderate-to-severe PVL and determine the optimal oversizing cut-off value.
We conducted a multicenter study that included 740 consecutive patients with multidetector computed tomography (CT) data. Valve size was selected according to manufacturer recommendations, with oversizing ranging from 10% to 30%. The primary endpoint was moderate-to-severe PVL.
The median age was 84 years (79-87 years), with 58.4% women, and a median EuroSCORE II of 4.1% (2.4-7.3%). Moderate-to-severe PVL was observed in 7.0% of the patients. An inverse relationship was found between oversizing and both PVL (11.3%, 8.6%, 5.4%, and 2.7% for quartiles Q1 to Q4; P = .007) and the need for post-dilation (P = .016). The multivariable analysis showed an association between oversizing and PVL (OR: 0.915 for each 1%-increase, P = .002). The optimal oversizing cut-off value to predict PVL was 20%, and PVL was significantly higher in patients with oversizing less than 20% (10.5% vs.4.2%, P less than .001). There were no differences in major clinical events according to the degree of oversizing, and a higher oversizing did not translate into an increased risk of permanent pacemaker (18.4% vs18.3%, P = .976).
In TAVR with the Evolut valve, a higher oversizing was associated with lower rates of moderate-to-severe PVL and a lower need for post-dilation, with no negative impact on procedural and early clinical outcomes. A 20% oversizing threshold could be suggested to reduce PVLs. Further prospective studies are warranted to validate optimal oversizing for this valve system.
瓣环扩大与减少瓣周漏(PVL)和瓣膜迁移风险有关。然而,尚未为 Evolut 系统(美敦力)定义最佳的瓣环扩大值。本研究旨在评估瓣环扩大程度与中重度 PVL 之间的关系,并确定最佳瓣环扩大的截断值。
我们进行了一项多中心研究,纳入了 740 例连续行多排 CT(MDCT)检查的患者。根据制造商的建议选择瓣膜尺寸,瓣环扩大 10%至 30%。主要终点是中重度 PVL。
患者中位年龄为 84 岁(79-87 岁),女性占 58.4%,EuroSCORE II 中位数为 4.1%(2.4-7.3%)。7.0%的患者发生中重度 PVL。瓣环扩大与 PVL(第 Q1 至 Q4 四分位数分别为 11.3%、8.6%、5.4%和 2.7%;P=0.007)和需要后扩张呈负相关(P=0.016)。多变量分析显示瓣环扩大与 PVL 相关(每增加 1%,OR:0.915,P=0.002)。预测 PVL 的最佳瓣环扩大截断值为 20%,瓣环扩大小于 20%的患者 PVL 明显更高(10.5%比 4.2%,P<0.001)。根据瓣环扩大程度,主要临床事件无差异,瓣环扩大程度较高并不增加永久性起搏器植入的风险(18.4%比 18.3%,P=0.976)。
在 Evolut 瓣膜行经导管主动脉瓣置换术(TAVR)中,瓣环扩大程度与中重度 PVL 发生率降低和后扩张需求减少相关,对手术和早期临床结局无负面影响。建议将 20%的瓣环扩大作为截断值以减少 PVL。需要进一步前瞻性研究来验证该瓣膜系统的最佳瓣环扩大。